Author

M. Meyerson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 8 Assay:bulk RNA-seq· 4 Approach:experimental assay· 4 Approach:statistical model· 4 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

J. A. DeCaprio· 3 shared J. Nomburg· 3 shared S. Bullman· 2 shared A. A. Tang· 1 shared A. D. Cherniack· 1 shared A. Goldstein· 1 shared A. Gupta· 1 shared A. J. Schulte· 1 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

J. A. DeCaprio

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Dosage amplification dictates oncogenic regulation by the NKX2-1 lineage factor in lung adenocarcinoma

J. L. Pulice, M. Meyerson

The paper identifies NKX2-1 dosage amplification as a critical driver in lung adenocarcinoma, showing it regulates enhancer accessibility, lineage addiction, and EGFR inhibitor resistance.

bioRxiv · Oct 26, 2023Cancer Biology

XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells

T. Zou, M. Zhou, A. Gupta, P. Zhuang, A. R. Fishbein, H. Y. Wei, Z. Zhang, A. D. Cherniack, M. Meyerson

The paper shows that deleting XRN1 activates PKR and kills cancer cells with high interferon expression, suggesting XRN1 as a therapeutic target.

bioRxiv · Aug 1, 2023Cancer Biology

Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker

M. S. Taylor, W. Connie, P. C. Fridy, S. J. Zhang, Y. Senussi, J. C. Wolters, W.-C. Cheng, J. Heaps, B. D. Miller, K. Mori, L. Cohen, H. Jiang, K. R. Molloy, B. L. Norden, B. T. Chait, , O. H. Yilmaz

This study develops ultrasensitive assays to detect ORF1p in plasma, showing its potential as a multi-cancer biomarker for early detection and monitoring.

bioRxiv · Jan 25, 2023 · PreprintCancer Biology

The Transcriptome Architecture of Polyomaviruses

J. Nomburg, W. Zou, T. C. Frost, C. Datta, S. Vasudevan, G. J. Starrett, M. J. Imperiale, M. Meyerson, J. A. DeCaprio

The paper characterizes the transcriptome architecture of polyomaviruses using RNA sequencing data, revealing pervasive wraparound transcription and novel conserved transcripts.

bioRxiv · Nov 12, 2021 · PreprintMicrobiology

An international report on bacterial communities in esophageal squamous cell carcinoma

J. Nomburg, S. Bullman, D. Nasrollahzadeh, E. A. Collisson, B. Abedi-Ardekani, L. O. Akoko, J. R. Atkins, G. C. Buckle, S. Gopal, N. Hu, B. Kaimila, M. Khoshnia, R. Malekzadeh, D. Menya, B. T. Mmbaga, , K. Van Loon

This study identifies bacterial communities associated with esophageal squamous cell carcinoma (ESCC) tumors and finds similar enrichment of oral bacteria in both saliva and tumor microbiomes of ESCC patients.

bioRxiv · Sep 29, 2021Microbiology

Hemangiosarcoma Cells Promote Conserved Host-Derived Hematopoietic Expansion

J. H. Kim, A. J. Schulte, A. L. Sarver, M. G. Angelos, A. M. Frantz, C. L. Foster, T. D. O'Brien, I. Cornax, M. G. O'Sullivan, N. Cheng, M. Lewellen, L. Oseth, S. Kumar, S. Bullman, C. S. Pedamallu, , J. F. Modiano

This study shows that hemangiosarcoma cells create a microenvironment that supports hematopoietic expansion, resembling bone marrow niche cells.

bioRxiv · May 21, 2021Cancer Biology

Pervasive generation of non-canonical subgenomic RNAs by SARS-CoV-2

J. Nomburg, M. Meyerson, J. A. DeCaprio

This study identifies canonical and non-canonical subgenomic RNAs in SARS-CoV-2, showing their consistent generation across isolates and infection conditions.

bioRxiv · Apr 28, 2020Microbiology

Non-oncology drugs are a source of previously unappreciated anti-cancer activity

S. M. Corsello, R. T. Nagari, R. D. Spangler, J. Rossen, M. Kocak, J. G. Bryan, R. Humeidi, D. Peck, X. Wu, A. A. Tang, V. M. Wang, S. A. Bender, E. Lemire, R. Narayan, P. Montgomery, , T. R. Golub

The paper identifies non-oncology drugs with anti-cancer activity across 578 cancer cell lines using PRISM, finding that many drugs selectively inhibit cancer cells based on molecular features.

bioRxiv · Aug 9, 2019Cancer Biology